CAPS — Capstone Therapeutics Share Price
Last trade - 00:00- $9.76m
- $12.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Capstone Therapeutics Corp. operates, through its wholly owned subsidiary, TotalStone, LLC (TotalStone). TotalStone is a materials distribution company, which distributes masonry stone products for residential and commercial construction in the Midwest and Northeast United States under the trade names Instone and Northeast Masonry Distributors. Its subsidiaries include Diamond Products Holdings, LLC, TotalStone Properties, LLC, Capstone Beta LLC, and Northeast Masonry Distributors, LLC.
Directors
- John Holliman CHM (61)
- Leslie Taeger CFO (65)
- Randolph Steer OTH (71)
- Fredric Feldman DRC (76)
- Matthew Lipman DRC (42)
- Michael Toporek DRC (56)
- Elwood Howse IND (75)
- Last Annual
- December 31st, 2019
- Last Interim
- December 31st, 2019
- Incorporated
- September 26th, 2008
- Public Since
- February 4th, 1993
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,190,251
- Address
- 5141 W. 122Nd Street, ALSIP, 60803
- Web
- Phone
- +1 6022865520
- Contact
- Barbara Dunford
- Auditors
- Eide Bailly, L.L.P.
Upcoming Events for CAPS
Similar to CAPS
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 19:47 UTC, shares in Capstone Therapeutics are trading at $1.88. This share price information is delayed by 15 minutes.
Shares in Capstone Therapeutics last closed at $1.88 and the price had moved by -63.85% over the past 365 days. In terms of relative price strength the Capstone Therapeutics share price has underperformed the S&P500 Index by -67.4% over the past year.
The overall consensus recommendation for Capstone Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCapstone Therapeutics does not currently pay a dividend.
Capstone Therapeutics does not currently pay a dividend.
Capstone Therapeutics does not currently pay a dividend.
To buy shares in Capstone Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.88, shares in Capstone Therapeutics had a market capitalisation of $9.76m.
Here are the trading details for Capstone Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CAPS
Based on an overall assessment of its quality, value and momentum Capstone Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Capstone Therapeutics is $6.00. That is 219.15% above the last closing price of $1.88.
Analysts covering Capstone Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Capstone Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -40.98%.
As of the last closing price of $1.88, shares in Capstone Therapeutics were trading -88.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Capstone Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Capstone Therapeutics' management team is headed by:
- John Holliman - CHM
- Leslie Taeger - CFO
- Randolph Steer - OTH
- Fredric Feldman - DRC
- Matthew Lipman - DRC
- Michael Toporek - DRC
- Elwood Howse - IND